Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives $205.67 Average Target Price from Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned an average rating of “Moderate Buy” from the seventeen brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $205.6667.

A number of equities research analysts have weighed in on JAZZ shares. Bank of America lifted their price target on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday. Morgan Stanley reissued an “overweight” rating and issued a $225.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, January 8th. UBS Group restated a “neutral” rating and set a $188.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Finally, JPMorgan Chase & Co. decreased their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a report on Monday, October 27th.

Jazz Pharmaceuticals Trading Up 0.2%

Jazz Pharmaceuticals stock opened at $171.16 on Tuesday. The business has a 50 day moving average price of $166.25 and a two-hundred day moving average price of $139.09. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals has a 12 month low of $95.49 and a 12 month high of $182.99. The stock has a market cap of $10.40 billion, a price-to-earnings ratio of -28.20, a price-to-earnings-growth ratio of 0.76 and a beta of 0.27.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 3,415 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total transaction of $607,118.70. Following the completion of the transaction, the director directly owned 20,449 shares in the company, valued at $3,635,423.22. This represents a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bruce C. Cozadd sold 77,500 shares of the company’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the completion of the sale, the director directly owned 393,332 shares in the company, valued at approximately $69,938,362.92. The trade was a 16.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 123,791 shares of company stock valued at $21,991,850. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Large investors have recently bought and sold shares of the business. Philip James Wealth Mangement LLC grew its holdings in Jazz Pharmaceuticals by 42.0% during the 2nd quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock worth $1,676,000 after acquiring an additional 4,675 shares during the last quarter. State of Alaska Department of Revenue grew its stake in shares of Jazz Pharmaceuticals by 75.1% during the second quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock valued at $6,147,000 after purchasing an additional 24,850 shares during the last quarter. Kennedy Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $1,100,000. Wedge Capital Management L L P NC bought a new position in Jazz Pharmaceuticals in the 3rd quarter worth approximately $27,834,000. Finally, Voya Investment Management LLC raised its position in Jazz Pharmaceuticals by 67.1% in the 1st quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company’s stock worth $6,996,000 after purchasing an additional 22,628 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.